Advanced search
Publication Cover
Leukemia & Lymphoma Volume 64, 2023 - Issue 9
Submit an article Journal homepage
243
Views
0
CrossRef citations to date
0
Altmetric
Letters to the Editor

Phase 2 trial of umbralisib, ublituximab, and venetoclax in patients with relapsed/refractory mantle cell lymphoma

Danielle S. Wallacea Wilmot Cancer Institute and the Department of Medicine, University of Rochester Medical Center, Rochester, NY, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-9371-6777View further author information
ORCID Icon,
Chris Rowlandb TG Therapeutics, Inc, New York, NY, USAView further author information
,
Brian T. Hillc Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USAView further author information
,
Andrea M. Barand Department of Biostatistics and Computational Biology, University of Rochester, Rochester, NY, USAView further author information
,
Carla Casuloa Wilmot Cancer Institute and the Department of Medicine, University of Rochester Medical Center, Rochester, NY, USAView further author information
,
Patrick M. Reagana Wilmot Cancer Institute and the Department of Medicine, University of Rochester Medical Center, Rochester, NY, USAView further author information
,
Allison Winterc Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USAORCID Iconhttps://orcid.org/0000-0002-8437-7539View further author information
ORCID Icon,
Reem Karmalie Division of Hematology and Oncology, Northwestern University Feinberg School of Medicine; Robert H. Lurie Comprehensive Cancer Center, Chicago, IL, USAView further author information
,
Jane N. Wintere Division of Hematology and Oncology, Northwestern University Feinberg School of Medicine; Robert H. Lurie Comprehensive Cancer Center, Chicago, IL, USAView further author information
,
Leo I. Gordone Division of Hematology and Oncology, Northwestern University Feinberg School of Medicine; Robert H. Lurie Comprehensive Cancer Center, Chicago, IL, USAView further author information
,
Andrew Buib TG Therapeutics, Inc, New York, NY, USAView further author information
,
Peter Sportellib TG Therapeutics, Inc, New York, NY, USAView further author information
,
Hari P. Miskinb TG Therapeutics, Inc, New York, NY, USAView further author information
,
Michael S. Weissb TG Therapeutics, Inc, New York, NY, USAView further author information
,
Jonathan W. Friedberga Wilmot Cancer Institute and the Department of Medicine, University of Rochester Medical Center, Rochester, NY, USAView further author information
,
Shuo Mae Division of Hematology and Oncology, Northwestern University Feinberg School of Medicine; Robert H. Lurie Comprehensive Cancer Center, Chicago, IL, USAView further author information
&
Paul M. Barra Wilmot Cancer Institute and the Department of Medicine, University of Rochester Medical Center, Rochester, NY, USAView further author information
 show all
Pages 1579-1582 | Received 29 Apr 2023, Accepted 02 Jun 2023, Published online: 21 Jun 2023
 
Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days
Click to increase image sizeClick to decrease image sizeFree first page

Acknowledgements

DSW and PMB analyzed the data and wrote the paper. CR and AB analyzed the data, provided statistical support, and contributed to the paper. BTH, CC, PMR, AW, RK, JNW, LEO, AB, PS, HPM, MSW, JWF, SH, and PMB conducted the research, reviewed, and contributed to the paper.

Disclosure statement

DSW, AMB, JWF and JNW report no conflicts of interest.

BTH: Research funding and consulting fees from Genentech, Abbvie, and TG Therauetics

CC: Research funding from SecuraBio, Gilead, Genentech, and BMS

PMR: research funding from Roche/Genentech, consulting for Kite Pharma/Gilead and Caribou Biosciences

AW: consulting for Seattle Genetics, Janssen, AstraZeneca and ADC Therapeutics.

RK: Advisory Board for BMS, Gilead Sciences/Kite Pharma, Janssen, Pharmacyclics, Morphosys, Genentech/Roche, Calithera, Miltenyi, Lilly Oncology. Research Support: BMS, Takeda, BeiGene, Gilead Sciences/Kite, Calithera. Speakers Bureau: AstraZeneca, BeiGene, Morphosys

LIG: DSMB Janssen. Advisory Board: BMS and Kite. Co-founder: Zylem, Inc. Consulting: Ono Pharmaceuticals

SM; Speaker: Astrazeneca, Beigene, Janssen, Lilly, Pharmacyclics. Advisory board/consulting: Abbvie, Astrazeneca, Beigene, BMS, Genentech, Janssen, Pharmacyclics TG therapeutics

Research funding: Abbvie, Astrazeneca, Beigene, Juno, Janssen, Loxo, TG therapeutics.

PMB: Consulting for Abbvie/PCYC, Beigene, Gilead, BMS/Celgene, AstraZeneca, TG, Janssen, Regeneron, Seattle Genetics, Merck, Morphosys, Adaptive

CR, AB, PS, HPM, MSW report employment by TG Therapeutics

Additional information

Funding

Funding for this trial was provided by TG Therapeutics.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.